Business Description
Zeo ScientifiX Inc
NAICS : 325412
SIC : 2834
ISIN : US68621D2062
Total Employee Number:
20Description
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.38 | |||||
Equity-to-Asset | 0.18 | |||||
Debt-to-Equity | 0.48 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -23.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.8 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 18 | |||||
3-Year FCF Growth Rate | 45.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.82 | |||||
9-Day RSI | 49.53 | |||||
14-Day RSI | 47.29 | |||||
3-1 Month Momentum % | -6.38 | |||||
6-1 Month Momentum % | -30.39 | |||||
12-1 Month Momentum % | -5.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.05 | |||||
Quick Ratio | 0.83 | |||||
Cash Ratio | 0.59 | |||||
Days Inventory | 118.97 | |||||
Days Sales Outstanding | 5.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | -12.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.52 | |||||
Operating Margin % | -59.1 | |||||
Net Margin % | -55.59 | |||||
EBITDA Margin % | -53.4 | |||||
FCF Margin % | -18.99 | |||||
OCF Margin % | -17.88 | |||||
ROA % | -175.41 | |||||
ROIC % | -237.05 | |||||
3-Year ROIIC % | -188.19 | |||||
ROC (Joel Greenblatt) % | -656.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.76 | |||||
PB Ratio | 19.23 | |||||
Price-to-Tangible-Book | 19.44 | |||||
EV-to-EBIT | -3.21 | |||||
EV-to-EBITDA | -3.27 | |||||
EV-to-Revenue | 1.75 | |||||
EV-to-FCF | -9.2 | |||||
Price-to-GF-Value | 0.66 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
| Price-to-Net-Current-Asset-Value | 175 | |||||
Earnings Yield (Greenblatt) % | -31.15 | |||||
FCF Yield % | -9.67 |
Zeo ScientifiX Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zeo ScientifiX Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-09-15 | In 78 days | ||
| General meeting for 2025 | 2026-06-26 | 1.75 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-06-15 | 1.70 (-3.95%) | ||
| First quarter earnings results for 2026 | 2026-03-17 | 2.00 (+8.11%) | ||
| Annual report for 2025 | 2026-01-29 | 2.64 (+1.55%) | ||
| Third quarter earnings results for 2025 | 2025-09-15 | 1.50 (-1.38%) | ||
| Second quarter earnings results for 2025 | 2025-06-16 | 2.05 (+0.61%) | ||
| First quarter earnings results for 2025 | 2025-03-17 | 2.60 (-3.70%) | ||
| Annual report for 2024 | 2025-01-29 | 2.49 (+1.74%) | ||
| Third quarter earnings results for 2024 | 2024-09-16 | 2.05 (+1.49%) |
Show
Entries
Guru Commentaries on OTCPK:ZEOX
No articles.
Press Release
Articles on Zeo ScientifiX Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers